Major depressive disorder

IntelGenx Announces Shareholder Approval of atai Investment

Tuesday, May 11, 2021 - 8:34pm

IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

Key Points: 
  • IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.
  • atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
  • atai operates a decentralized model to enable scalable drug or technological development across its companies, seeking to effectively treat and ultimately heal mental health disorders.
  • More particularly and without limitation, this document contains forward-looking statements and information regarding the completion and anticipated timing of completion of the atai investment in IntelGenx.

Annals of Family Medicine: Psychotherapy and Pharmacotherapy are More Effective in Treating Depression when Paired Together in Primary Care

Tuesday, May 11, 2021 - 3:50pm

b'ANN ARBOR, Mich., May 11, 2021 /PRNewswire/ -- Most patients with depression are treated in primary care, and the majority of those patients prefer psychotherapy over treatment that includes medication (i.e., pharmacotherapy).

Key Points: 
  • b'ANN ARBOR, Mich., May 11, 2021 /PRNewswire/ -- Most patients with depression are treated in primary care, and the majority of those patients prefer psychotherapy over treatment that includes medication (i.e., pharmacotherapy).
  • Primary care physicians, however, are more likely to prescribe antidepressants to their patients suffering from depression.\nAlthough studies have shown the effectiveness of psychotherapy in primary care patients, researchers haven\'t yet examined the effects of psychotherapy compared with pharmacotherapy, combined treatment, and other clinical scenarios in primary care.\nIn a study published in the May/June, 2021 issue of Annals of Family Medicine, researchers examined the effects of psychotherapy compared with pharmacotherapy, combined treatment, care-as-usual, waitlist, and pill placebo in primary care patients.\nThe study is led by Pim Cuijpers, Ph.D., professor of clinical psychology in the Department of Clinical, Neuro and Development Psychology at Vrije Universiteit, The Netherlands, and includes collaborating authors from Japan, Spain, the U.K. and New Zealand.\nThe team integrated the results of 58 randomized controlled trials involving 9,301 patients.
  • "Treatments in primary care must be organized so as to accommodate any of these treatments in response to patients\' preferences and values.
  • "\nPsychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis\nVrije Universiteit Amsterdam, Department of Clinical, Neuro and Developmental Psychology; Amsterdam Public Health Research Institute; Vrije Universiteit, Amsterdam, The Netherlands.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/annals-of-family-medicine-psycho...\n'

Braxia Scientific Introduces "Braxia Health" a Growing Network of Clinics Leading Novel Psychedelic Research and Treatments for Mental Disorders

Friday, May 7, 2021 - 10:30pm

"In addition to providing clinical care with novel treatments to patients suffering from depression and other mental disorders, Braxia Health is an international leader in clinical research involving ketamine, psychedelic derivatives and other rapid-acting treatments.

Key Points: 
  • "In addition to providing clinical care with novel treatments to patients suffering from depression and other mental disorders, Braxia Health is an international leader in clinical research involving ketamine, psychedelic derivatives and other rapid-acting treatments.
  • Both treatments represent the first treatments for depression that are mechanistically different from the antidepressants that have been available for the past 70 years.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (Braxia Health) and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.\n'

Greenbrook TMS Announces Change of Dates for Its First Quarter 2021 Financial Results

Friday, May 7, 2021 - 1:30pm

b'For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.\nThe conference call replay will be available from 1:00 p.m.

Key Points: 
  • b'For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.\nThe conference call replay will be available from 1:00 p.m.
  • ET on May 17, 2021, until 11:59 p.m.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 620,000 TMS treatments to over 17,000 patients struggling with depression.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005172/en/\n'

MycoMeditations' Psilocybin-Assisted Wellness Retreat Urgently Addresses COVID-19's Impact on Mental Health

Wednesday, May 5, 2021 - 3:05pm

b'TREASURE BEACH, Jamaica, May 5, 2021 /PRNewswire/ -- MycoMeditations , a pioneering leader in the evolving fields of legal psychedelic therapy and wellness tourism, is urgently addressing COVID-19\'s psychological impact, as nearly a quarter of its guests have expressed that the mental and emotional burden catalyzed by the pandemic is a significant deterrent to their psychological well-being.\nWith vaccination rates increasing and more people becoming comfortable with travel, MycoMeditations sees a strong need to address the mental fallout from COVID-19 by offering a psychological healing experience in a safe, beautiful and caring setting.\n"Many of our guests have an urgent need to address the emotional and mental health burden of COVID-19," said Justin Townsend , MycoMeditation\'s CEO and Lead Facilitator.

Key Points: 
  • b'TREASURE BEACH, Jamaica, May 5, 2021 /PRNewswire/ -- MycoMeditations , a pioneering leader in the evolving fields of legal psychedelic therapy and wellness tourism, is urgently addressing COVID-19\'s psychological impact, as nearly a quarter of its guests have expressed that the mental and emotional burden catalyzed by the pandemic is a significant deterrent to their psychological well-being.\nWith vaccination rates increasing and more people becoming comfortable with travel, MycoMeditations sees a strong need to address the mental fallout from COVID-19 by offering a psychological healing experience in a safe, beautiful and caring setting.\n"Many of our guests have an urgent need to address the emotional and mental health burden of COVID-19," said Justin Townsend , MycoMeditation\'s CEO and Lead Facilitator.
  • "Guests have talked about the loss of loved ones, being hospitalized for COVID-19 and the everyday scenarios of living under the stress of COVID-19," he added.\nRecent data from the Centers for Disease Control and Prevention states COVID-19 has made it more challenging for people to access mental health services andindicates one in four adults reported experiencing symptoms of an anxiety or depressive disorder in February 2021, a significant increase from the prior year.\n"The combination of uncertainty and social distancing induced by the COVID-19 pandemic may lead to excessive fear, loneliness and depressive thoughts, and current studies show psilocybin\'s ability to relieve symptoms of depression, end of life anxiety, social stresses and PTSD," said Townsend.\nMycoMeditations guests are pre-screened prior to arriving for health-related issues so as to provide MycoMeditation\'s professional staff with insights of an individual\'s physical and mental state.
  • The guest to staff ratio is three to one or lower.\nWith a record of more than 750 guests successfully completing psilocybin-assisted retreats and a Five Star Rating on TripAdvisor , MycoMeditations offers proven, professional and personalized healing experiences for depression, anxiety, and other conditions in a safe, beautiful and caring setting.
  • All retreats are in compliance with health and safety protocols recommended by the Jamaican Ministry of Health and the World Health Organization involving COVID-19.\nMycoMeditations , a pioneering leader in the expanding fields of legal psychedelic therapy and wellness tourism is driven by its commitment to charting a new way forward for psychological care, therapeutics, research and legalization by providing safe, life-affirming experiences guided by expert facilitators and mental health professionals.\n'

Paradigm Treatment Opens New Center in San Rafael

Wednesday, May 5, 2021 - 2:11pm

b'SAN RAFAEL, Calif., May 5, 2021 /PRNewswire/ -- Paradigm Treatment with 7 locations in Malibu and in San Rafael, has been helping teens and young adults ages 12-26 with mental health issues for over 10 years, and just opened a new co-ed treatment facility in San Rafael specifically serving adolescents ages 12-17.\nThis location\'s specialty is treating mental health issues including but not limited to depression, anxiety, bipolar disorder as well as co-occurring substance use.

Key Points: 
  • b'SAN RAFAEL, Calif., May 5, 2021 /PRNewswire/ -- Paradigm Treatment with 7 locations in Malibu and in San Rafael, has been helping teens and young adults ages 12-26 with mental health issues for over 10 years, and just opened a new co-ed treatment facility in San Rafael specifically serving adolescents ages 12-17.\nThis location\'s specialty is treating mental health issues including but not limited to depression, anxiety, bipolar disorder as well as co-occurring substance use.
  • Paradigm provides a high staff to client ratio; their admissions screening process is comprehensive and their treatment team is uniquely qualified.
  • The center also conducts thorough diagnostic testing beforetreatment begins in order to inform the best course of treatment.
  • Paradigm prioritizes lasting efficacy as a cornerstone of its treatment philosophy, which empowers young clients to build and hone the skills they need to lead meaningful, productive lives, long after they complete the Paradigm program.

Braxia Scientific Introduces "Braxia Health" a Growing Network of Clinics Leading Novel Psychedelic Research and Treatments for Mental Disorders

Wednesday, May 5, 2021 - 12:05pm

"In addition to providing clinical care with novel treatments to patients suffering from depression and other mental disorders, Braxia Health is an international leader in clinical research involving ketamine, psychedelic derivatives and other rapid-acting treatments.

Key Points: 
  • "In addition to providing clinical care with novel treatments to patients suffering from depression and other mental disorders, Braxia Health is an international leader in clinical research involving ketamine, psychedelic derivatives and other rapid-acting treatments.
  • Both treatments represent the first treatments for depression that are mechanistically different from the antidepressants that have been available for the past 70 years.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (Braxia Health) and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.\n'

Greenbrook TMS Announces Preliminary First Quarter 2021 Operational and Financial Results

Tuesday, May 4, 2021 - 9:46pm

b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).

Key Points: 
  • b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).
  • We are proud of our team\xe2\x80\x99s efforts to continue to treat patients suffering from treatment resistant depression and obsessive-compulsive disorder during this difficult time.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.

Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in Houston; Locations of Next 5 Field Trip Health Centers

Tuesday, May 4, 2021 - 12:30pm

The academic data matches closely with what we are seeing in our Field Trip Health centers -- that psychedelic-assisted therapy is a safe and effective treatment for depression, anxiety and other mental health challenges,\xe2\x80\x9d commented Dr. Ben Medrano, Field Trip\xe2\x80\x99s Senior Vice President and U.S. Medical Director.

Key Points: 
  • The academic data matches closely with what we are seeing in our Field Trip Health centers -- that psychedelic-assisted therapy is a safe and effective treatment for depression, anxiety and other mental health challenges,\xe2\x80\x9d commented Dr. Ben Medrano, Field Trip\xe2\x80\x99s Senior Vice President and U.S. Medical Director.
  • Each Field Trip Health center is designed to promote healing and provide people with a calming space before, during, and after treatment, and Houston is no different.
  • A great deal of consideration and thought also goes into making each Field Trip Health center suited for the community it serves.
  • Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Tuesday, May 4, 2021 - 11:30am

Zuranolone has received breakthrough therapy designation from the FDA for the treatment of major depressive disorder (MDD).

Key Points: 
  • Zuranolone has received breakthrough therapy designation from the FDA for the treatment of major depressive disorder (MDD).
  • Sage is jointly developing zuranolone in the U.S. with Biogen.\nZuranolone is being evaluated as a potential rapid-acting, short-course treatment for PPD and MDD in the NEST and LANDSCAPE clinical trial programs.
  • The SHORELINE Study is designed to evaluate the safety and tolerability of zuranolone in adults for up to one year.
  • Sage is jointly developing SAGE-324 in the U.S. with Biogen.\nIn April 2021, Sage reported topline data from the KINETIC Study evaluating SAGE-324 in the treatment of people with ET.